AI in Biotech: Roles, Skills & Hiring Implications (2026)

This piece looks at where AI is genuinely changing the talent landscape in biotech, what that means for the roles organisations are hiring for, and how hiring leaders can build a more deliberate response.

AI is reshaping biotechnology faster than most hiring strategies have adapted.

New roles are emerging, existing ones are evolving, and the skills organisations assumed were sufficient twelve months ago are already being reassessed. Yet across much of the sector, the hiring response remains reactive, driven by immediate vacancies rather than by a considered view of what capabilities are actually needed.

The conversation about AI in biotechnology has moved on. It is no longer a question of whether AI will change how the sector operates - it already is. What varies is how deeply that change is embedded across organisations. For hiring leaders, the more pressing question is whether their talent strategy reflects that reality.

What we observe across biotech is a sector in genuine transition. Teams structured around traditional scientific workflows are being asked to integrate AI-driven tooling, interpret outputs from machine learning models, and collaborate with profiles that did not exist in their organisations two years ago.

In many cases, science has moved faster than the people's strategy designed to support it. That gap is where much of the hiring challenge currently sits.

It is worth being specific, because broad claims that “AI is transforming everything” are less useful than understanding where the change is actually concentrated. In drug discovery and target identification, AI-driven approaches are helping compress parts of workflows that previously took significant time - particularly in data analysis, target prioritisation, and early-stage design.

What is less clear is the extent to which this translates into end-to-end compression of drug development timelines. The evidence today points more strongly to task-level acceleration than systemic change across the full pipeline. The implication is not that computational biologists have replaced bench scientists. It is that scientists who cannot engage with computational outputs are increasingly working at a disadvantage.

In clinical development, AI is being applied to patient stratification, trial design optimisation, and real-world evidence synthesis. However, we see that adoption remains uneven. The limiting factors are not only technical, but also linked to validation, explainability, and regulatory confidence.

The roles required to support this work sit at an intersection that few traditional clinical career paths have prepared people for. In manufacturing and process development, AI is beginning to influence areas such as predictive quality systems and process monitoring. Regulatory expectations around how these systems should be validated and governed are evolving.

The pattern across all three areas is consistent: AI is not replacing scientific expertise. It is raising the floor of what scientific expertise needs to include.

The short answer is yes - but the picture is more nuanced than the volume of job postings might suggest.

There is clear investment in AI and data capability across biotech. In practice, this is showing up through:

• targeted hiring into highly specialised roles
• expansion of responsibilities within existing roles
• and accelerated upskilling of current teams

In a market where overall hiring remains cautious, this is less a hiring surge and more a reallocation of demand toward specific capabilities.

Several profiles are now appearing with enough consistency to warrant attention from hiring leaders:

Machine Learning Scientists with biological domain knowledge: These sit at the centre of many AI-driven discovery programmes. The challenge is that genuine depth in both areas remains rare.

AI/ML platform and infrastructure roles: As organisations move from using third-party tools to building internal capability, demand is growing for profiles who can support these environments - often requiring at least some scientific context.

Bridging profiles between data and application: Particularly in clinical, regulatory, and operational contexts, there is an increasing need for individuals who can translate AI-generated insights into real-world decisions. These are still emerging patterns rather than fully standardised roles, but they are becoming more visible across the market.

The emergence of new roles tells only part of the story. For most biotech organisations, the more immediate challenge is the evolution of existing ones.

Roles across QA, bioinformatics, clinical data management, and medical writing are all being reshaped by AI tooling - sometimes gradually, sometimes abruptly. Professionals are being asked to adapt, often without a clear organisational view of what that adaptation should look like.

The hiring implication is significant. Organisations are no longer hiring for static competencies. They are hiring for the ability to operate in roles that will continue to evolve.

When we look at people working where biotech and AI overlap, there are a few skills that consistently show up:

• Data literacy
• Increasingly important across many scientific and operational roles
• Biological domain knowledge applied to model use
• Understanding which problems are tractable with current AI approaches
• Interpretability and critical evaluation of outputs
• The ability to interrogate models, not just use them
• Cross-functional communication
• Translating between scientific, technical, and regulatory perspectives
• Regulatory and ethical awareness
• As AI moves closer to regulated decision-making environments

What this looks like in practice varies widely by role - the level of AI capability required from a QA professional is not the same as for a computational biologist.

This question tends to come up when organisations realise the market is not behaving as they expected. Contingent search works well when the role is clearly defined, the talent pool is visible, and there is enough active movement in the market to generate options quickly.

The challenge is that many AI and computational roles in biotech do not meet those conditions. A more retained or dedicated approach becomes materially more effective when:

• The role is genuinely specialist and where credible candidates are limited and rarely active on the market
• The brief is still evolving, which is often the case in AI-related hiring, where organisations are hiring for capability, not just a job description
• The hire carries strategic weight, and getting it wrong has a downstream impact on programmes, team structure, or delivery timelines
• The visible market is not the real market, and the right profiles need to be identified, engaged, and converted proactively
• Previous searches have produced volume, but not quality, which is usually a signal that the approach, not just the candidates, needs to change

What this comes down to is less about preference and more about fit to complexity. When the role is difficult to define, find, or assess, a contingent model often struggles to gain traction. A more retained approach enables deeper exploration of the market, a tighter definition of the brief, and a more controlled process.

The organisations that recognise this early, rather than after several months of stalled search, tend to hire more effectively into their most critical roles.

The organisations navigating this well are not necessarily those with the largest AI programmes. They are the ones who have taken a deliberate view of capability.

In practice, that looks like:

• defining AI literacy by function, rather than applying a uniform standard
• widening the search to adjacent sectors where appropriate
• building development pathways alongside hiring strategies
• and updating interview processes to assess how candidates engage with AI outputs

The most important thing to understand about AI in biotech hiring is that it is not a specialist problem for specialist teams. It is a structural shift reshaping what scientific and operational capabilities should look like.

Organisations that respond well will not be those chasing every new role that appears. They will be the ones who understand clearly what they need, where the gaps are, and how to build for a function that will continue to evolve.